AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.

RegulatoryapprovedMAVYRETPositive

AI Analysis

Summary

AbbVie's MAVYRET became the first oral antiviral approved for acute hepatitis C infection in June 2025, demonstrating a 96% cure rate in clinical trials. The article notes a gap between trial efficacy and real-world treatment outcomes, highlighting challenges in addressing the rising HCV infection rate in the United States.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

First antiviral cleared for acute HCV infection with 96% cure rate in trial

Importance:7/10

Sentiment:

0.60

Hepatitis CAntiviralFDA ApprovalCure RateAcute Infection

Related Companies

$ABBV

Read the original article

Published by Drug Discovery & Development on August 28, 2026 4:49 PM

Read Original